Trial reportPsychopharmacology2013
Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.
Trial report in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 47 citations in OpenAlex.
- Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study.Translational psychiatry · 2026Trial
- Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Human Pharmacology of Mephedrone in Comparison with MDMA.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Trial
- Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use.Molecular psychiatry · 2026Review
- Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.Disease-a-month : DM · 2025Review
- MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis.CPT: pharmacometrics & systems pharmacology · 2025Article
- Chemical composition of Ecstasy tablets seized in Poland between 2005 and 2020.Forensic toxicology · 2025Article
- No significant gender differences in driving-related skills following alcohol mixed with energy drinks during an experimental binge-drinking episode.Frontiers in pharmacology · 2025Article
- Lack of evidence for positive reinforcing and prosocial effects of MDMA in pair-housed male and female rats.European journal of pharmacology · 2021Article
- Soy Isoflavone Extract Does Not Increase the Intoxicating Effects of Acute Alcohol Ingestion in Human Volunteers.Frontiers in pharmacology · 2019Article
- Mephedrone and Alcohol Interactions in Humans.Frontiers in pharmacology · 2019Article
- Progress and promise for the MDMA drug development program.Psychopharmacology · 2018Review
- Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions.BioMed research international · 2015Article
- 3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration.Analytical and bioanalytical chemistry · 2014Article
- Behavioral effects and pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboons.The Journal of pharmacology and experimental therapeutics · 2013Article
- 3,4-methylenedioxymethamphetamine (MDMA): current perspectives.Substance abuse and rehabilitation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most abused recreational drugs. Its usual pattern of misuse includes repeated doses taken over a short time period that could influence MDMA pharmacology and toxicity.
objectiveThis study aims to evaluate the pharmacokinetics and pharmacologically induced effects of two MDMA consecutive doses separated by 2 h.
methodsA randomized, double-blind, crossover, and placebo-controlled trial included ten male volunteers participating in two experimental sessions. MDMA was administered as a single 100-mg dose or as a repeated dose (50 mg followed by 100 mg, administered at 2 h apart). Outcome variables included pharmacokinetics, physiological, subjective, and psychomotor effects.
resultsFollowing the repeated doses, plasma concentrations of MDMA were higher than those expected by simple dose accumulation (+16.2 % AUC; +12.8 % C (max)), but those of HMMA and HMA were significantly lower (-29.8 % AUC; -38.2 % C (max)). After the second dose, physiological effects, psychomotor performance, and subjective effects were lower than expected especially for euphoria and stimulation. MDMA-induced increases in diastolic and systolic arterial pressure and body temperature were in the range of those expected following MDMA concentrations.
conclusionsMDMA pharmacokinetics and metabolic disposition following two doses separated by 2 h show that the contribution of the first dose to the MDMA-induced mechanism-based metabolic inhibition was already apparent. The concentrations of MDMA after the second dose were slightly higher than expected. The effects on blood pressure and temperature after the second administration were slightly higher than those following the first, but for heart rate and subjective variables these were lower than expected considering the MDMA concentrations achieved, suggesting a possible tolerance phenomenon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.